Global Blood Therapeutics

About:

GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.

Website: http://www.gbt.com/

Twitter/X: gbt_news

Top Investors: Wellington Management, Deerfield, RA Capital Management, Third Rock Ventures, Sabby Capital

Description:

GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and is headquartered in San Francisco, California.